Neurotrope, Inc. (NTRP) financial statements (2021 and earlier)

Company profile

Business Address 1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 17291626118
Cash and cash equivalents 17291626118
Prepaid expense 010010
Other undisclosed current assets     0 
Total current assets: 18291626138
Noncurrent Assets
Property, plant and equipment 000000
Total noncurrent assets: 000000
TOTAL ASSETS: 18291626138
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 032211
Accounts payable 031201
Accrued liabilities 000000
Debt     0 
Due to related parties   000 
Other undisclosed current liabilities      0
Total current liabilities: 032211
Noncurrent Liabilities
Total liabilities: 032211
Stockholders' equity
Stockholders' equity attributable to parent 17271524(0)(12)
Common stock 000000
Additional paid in capital 1061007874287
Accumulated deficit (89)(74)(63)(50)(28)(18)
Total stockholders' equity: 17271524(0)(12)
Other undisclosed liabilities and equity     1219
TOTAL LIABILITIES AND EQUITY: 18291626138

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:  (0)  (2) 
Operating expenses (16)(11)(13)(13)(9)(9)
Operating loss: (16)(11)(13)(13)(11)(9)
Nonoperating income (expense)
(gain on Contract Termination)
   0   
Other undisclosed income from continuing operations before equity method investments, income taxes 000020
Net loss attributable to parent: (15)(11)(13)(13)(9)(9)
Preferred stock dividends and other adjustments     (0)(2)
Net loss available to common stockholders, diluted: (15)(11)(13)(13)(10)(11)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (15)(11)(13)(13)(9)(9)
Comprehensive loss, net of tax, attributable to parent: (15)(11)(13)(13)(9)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: